CARP-1-NEMO Inhibitor Overcomes Doxorubicin Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Resistance to doxorubicin, a chemotherapeutic agent, among cancer cells poses a barrier to effective cancer treatment, necessitating new approaches to enhance chemotherapy efficacy and overcome resistance.
Innovation Solution
Administering a therapeutically effective amount of a CARP-1-NEMO inhibitor to inhibit cell cycle progression, DNA repair, and chemotherapeutic resistance, while enhancing the efficacy of chemotherapy and reducing toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If doxorubicin is administered to treat cancer, then cancer cell growth is inhibited, but chemotherapeutic resistance develops reducing treatment efficacy
Solution Approach 1:
The patent introduces CARP-1-NEMO inhibitor as an intermediary substance that mediates between doxorubicin and cancer cells. The inhibitor blocks the CARP-1/NEMO interaction pathway that cancer cells use to develop resistance, thereby enhancing doxorubicin's effectiveness without requiring changes to the chemotherapeutic agent itself
Solution Approach 2:
The patent changes the biochemical parameters of the cancer cell environment by introducing a small molecule inhibitor that alters the CARP-1/NEMO binding affinity. This parameter change prevents the resistance mechanism from activating, maintaining doxorubicin's cytotoxic effect on cancer cells
2Productivity
If chemotherapeutic agents are administered to inhibit cancer cell growth, then tumor progression is slowed, but systemic toxicity increases affecting healthy tissues
Solution Approach 1:
The CARP-1-NEMO inhibitor serves as a protective intermediary that modulates the signaling pathway in healthy tissues. By blocking this specific interaction, the inhibitor reduces the harmful effects of chemotherapeutic agents on normal cells while preserving their anti-tumor activity
Solution Approach 2:
The patent applies local quality by targeting the CARP-1/NEMO interaction specifically in the context of chemotherapeutic response. The inhibitor selectively modulates this pathway in tissues affected by chemotherapy, providing localized protection against toxicity without compromising overall treatment efficacy
3Ease of operation
If cancer cells are treated with conventional chemotherapy, then cell division is arrested, but DNA repair mechanisms are activated enabling resistance
Solution Approach 1:
The CARP-1-NEMO inhibitor is administered in combination with or prior to chemotherapeutic agents to preemptively block the DNA repair pathway. By inhibiting the CARP-1/NEMO interaction before chemotherapeutic damage occurs, the patent prevents cancer cells from activating their DNA repair mechanisms in response to treatment
Solution Approach 2:
The inhibitor performs preliminary anti-action by counteracting the DNA repair response that cancer cells would normally activate following chemotherapeutic exposure. The CARP-1/NEMO blockade prevents the pro-survival signaling that would otherwise enable cells to recover from chemotherapy-induced DNA damage
Data Source
AI summary
Described herein are compositions and methods for treating cancer in a subject. The compositions include selective NF-κB inhibitor inhibitors. The methods include inhibiting the binding of CARP-1 with NEMO.